Novartis Can't DQ Rival's Atty In Drug IP Row, Report Says
A special master recommended Thursday that a Delaware federal court rebuff Novartis' bid to disqualify one of its competitor's attorneys in a drug patent suit over the multiple sclerosis treatment Gilenya,...To view the full article, register now.
Already a subscriber? Click here to view full article